---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-394492"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-09-17T21:05:24+00:00"
generated_at: "2026-09-17T21:06:21.289009+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Tempest secures exclusive option to license Senlang's CD7-targeted in vivo CAR-T platform

## Summary
- Option exercisable within 4 months for ~$447,000 fee; exclusive license for ex-Greater China rights.
- Post-exercise fees: annual maintenance $10M-$14M over first 3 years, 6% net-sales royalty, sublicense revenue share.
- Lead BCMA/GPRC5D dual-targeting candidate in Phase 1 for relapsed/refractory multiple myeloma; early in vivo CAR-T generation observed.
- As of Aug 25, 2026, no Grade 3+ CRS or ICANS; safety profile supports continued dose escalation.
- Agreement complements Tempest's existing LNP platform; expands portfolio to hematologic and autoimmune indications.

## SEC filing metadata
- accession: 0001193125-26-394492
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-09-17T21:05:24+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/0001193125-26-394492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/d185404d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-394492
- JSON: https://secwatch.observer/filing/0001193125-26-394492.json
- Plain text: https://secwatch.observer/filing/0001193125-26-394492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.